Table 2 The comparison between anxiety group and non-anxiety group
From: Effects of treatment status and life quality on anxiety in MMT patients
Anxiety group (n=54) | Non-anxiety group (n=123) | p-value | |
|---|---|---|---|
Gender (males/females) | 45(83.3%)/9(16.7%) | 110(89.4%)/13(10.6%) | 0.26 |
Age | 51.0±5.1 | 52.2±5.9 | 0.20 |
Years of education | |||
≤9 | 40(74.1%) | 91(74.0%) | 0.63 |
10–12 | 14(25.9%) | 30(24.4%) | |
≥13 | – | 2(1.6%) | |
Marital status (single/married) | 30(55.6%)/24(44.4%) | 68(55.3%)/55(44.7%) | 0.97 |
Living situation (alone/with partners) | 21(38.9%)/33(61.1%) | 36(29.3%)/87(70.7%) | 0.23 |
Drinking status (yes/no) | 16(29.6%)/38(70.4%) | 42(34.1%)/81(65.9%) | 0.56 |
Smoking status (yes/no) | 54(100.0%)/− | 120(97.6%)/3(2.7%) | 0.25 |
Cumulative duration of heroin use (month) | 253.9±76.3 | 264.7±85.3 | 0.43 |
Cumulative duration of MMT (month) | 113.4±53.1 | 95.4±63.4 | 0.07 |
Current methadone therapeutic dose (mg) | 42.7±19.2 | 34.9±22.9 | 0.03* |
MMT Interruption (yes/no) | 30(55.6%)/24(44.4%) | 42(34.1%)/81(65.9%) | 0.008** |
QOL-DA total score | 143.13±22.3 | 172.46±13.52 | <0.01** |